Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 113
- Registration Number
- NCT04004221
- Locations
- 🇨🇳
Fudan University Hua Dong Hospital, Shanghai, Shanghai, China
🇨🇳Xiangya Hospital central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 420
- Registration Number
- NCT03967977
- Locations
- 🇨🇳
The Second Affiliated Hospital of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 370
- Registration Number
- NCT03957590
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Northern Jiangsu people's hospital, Yangzhou, Jiangsu, China
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT03941873
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT03924986
- Locations
- 🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 649
- Registration Number
- NCT03783442
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 997
- Registration Number
- NCT03777657
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇫🇷CHU Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷Hôpital de la Timone, Marseille, France
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT03745222
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸Dayton Physicians, LLC, Kettering, Ohio, United States
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 358
- Registration Number
- NCT03744468
- Locations
- 🇮🇹
Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy
🇫🇷Centre de Lutte Contre Le Cancer Francois Baclesse, Caen, France
🇮🇹Istituto Di Candiolo Irccs, Torino, Italy
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 216
- Registration Number
- NCT03666143
- Locations
- 🇦🇺
Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.